High-dose methadone and QTc prolongation: Strategies to optimize safety

John Schmittner, MD; Mori J. Krantz, MD

doi:10.5055/jom.2006.0008

Authors

John Schmittner, MD
Mori J. Krantz, MD

DOI:

https://doi.org/10.5055/jom.2006.0008

Keywords:

-

Abstract

-

Author Biographies

John Schmittner, MD

Clinical Pharmacology and Therapeutics Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland.

Mori J. Krantz, MD

Department of Medicine, Cardiology Division, Denver Health Medical Center, and Colorado Prevention Center, Denver, Colorado.

References

Khan IA: Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med. 2002; 112(1): 58-66.

Khan IA: Long QT syndrome: Diagnosis and management. Am Heart J. 2002; 143(1): 7-14.

Bednar M, Harrigan E, Anziano R, et al.: The QT interval. Prog Cardiovasc Dis. 2001; 43(5): 1-45.

Vincent M: The long-QT syndrome—Bedside to bench to bedside. N Engl J Med. 2003; 348(19): 1837-1838.

Roden D: Drug-induced prolongation of the QT interval. N Engl J Med. 2004; 350(10): 1013-1022.

Committee for Proprietary Medicinal Products: Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. Paper presented at European Agency for the Evaluation of Medicinal Products, 1997, London, England.

Morganroth J: A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment. J Electrocardiol. 2004; 37(1): 25-29.

Malik M, Camm A: Evaluation of drug-induced QT interval prolongation. Drug Saf. 2001; 24(5): 323-351.

Haverkamp W, Breithardt G, Camm AJ, et al.: The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications report on a policy conference of the European Society of Cardiology. Cardiovasc Res. 2000; 47(2): 219-233.

Deamer RL, Wilson DR, Clark DS, et al.: Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM®). J Addict Dis. 2001; 20(4): 7-14.

Products. EAftEoM. EMEA public statement to suspend the marketing authorization for Orlaam (Levacetylmethadol) in the European Union. Available online at: http://www.emea.eu.int/ pdfs/human/press/plus/877601en.pdf.

Gil M, Sala M, Anguera I, et al.: QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol. 2003; 92(8): 995-997.

Krantz MJ, Lewkowiez L, Hays H, et al.: Torsade de Pointes associated with very-high-dose methadone. Ann Intern Med. 2002; 137(6): 501-504.

Krantz MJ, Mehler PS: Treating opioid dependence— Growing implications for primary care. Arch Intern Med. 2004; 164(3): 277-288.

Krantz MJ, Rowan SB, Mehler PS: Cocaine-related Torsade de Pointes in a methadone maintenance patient. J Addict Dis. 2005; 24(1): 53-60.

Walker P, Klein K, Kasza L: High dose methadone and ventricular arrhythmias: A report of three cases. Pain. 2003; 103: 321-324.

Martell BA, Arnsten JH, Ray B, et al.: The impact of methadone induction on cardiac conduction in opiate users. Ann Intern Med. 2003; 139(2): 154-155.

Martell BA, Arnsten JH, Krantz MJ, et al.: Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol. 2005; 95(7): 915-918.

Krantz MJ, Garcia JA, Mehler PS: Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacotherapy. 2005; 25(4): 611-614.

De Bels D, Starourkine M, Devriendt J: Torsades de pointes due to methadone. Ann Intern Med. 2003; 139(2): E156.

Krantz MJ, Martell BA, Arnsten JH, et al.: Medications that prolong the QT interval. JAMA. 2003; 290(8): 1025.

Sala M, Anguera I, Cervantes M: Torsades de pointes due to methadone. Ann Intern Med. 2003; 139(4): W64.

Krantz MJ, Kutinsky IB, Robertson AD, et al.: Dose-related effects of methadone on QT prolongation in a series of patients with Torsade de Pointes. Pharmacotherapy. 2003; 23(6): 802-805.

Katchman AN, McGroary KA, Kilborn MJ, et al.: Influence of opioid agonists on cardiac human ether-a-go-go related gene K+ currents. J Pharmacol Exp Ther. 2002; 303(2): 688-694.

Vincent GM: Long QT syndrome. Cardiol Clin. 2000; 18: 309-325.

Viskin S: Long QT syndromes and torsade de pointes. Lancet. 1999; 354(9190): 1625-1633.

Ripamonti C, Bianchi M: The use of methadone for cancer pain. Hematol Oncol Clin North Am. 2002; 16(3): 543-555.

Mercadante S, Casuccio A, Fulfaro F, et al.: Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: A prospective study. J Clin Oncol. 2001; 19(11): 2898-2904.

Manzi SF, Shannon M: Drug interactions—A review. Clin Pediatr Emerg Med. 2005; 6(2): 93-102.

Cohen OJ, Fauci AS: Current strategies in the treatment of HIV infection. Disease-A-Month. 2002; 48(3): 150-184.

Lucchini A, Barbaro G, Barbarini G: Methadone and QT prolongation in HIV-infected patients. Am J Cardiol. 2004; 94(1): 147-148.

The University of Arizona Center for Education and Research on Therapeutics: http://www.torsades.org.

Krantz MJ, Mehler PS. Methadone and QT prolongation: A dose-dependent effect? Am J Cardiol. 2004; 93(7): 952.

Hollander J, Lozano M, Fairweather P, et al.: Abnormal electrocardiograms in patients with cocaine-associated chest pain are due to “normal” variants. J Emerg Med. 1994; 12(2): 199-205.

Lehmann M, Morady F: QT interval: Metric for cardiac prognosis? Am J Med. 2003; 115(9): 732-734.

Viskin S, Rosovski U, Sands AJ, et al.: Inaccurate electrocardiographic interpretation of long QT: The majority of physicians cannot recognize a long QT when they see one. Heart Rhythm. 2005; 2(6): 569-574.

Krahn A, Nguyen-Ho P, Klein G, et al.: QT dispersion: An electrocardiographic derivative of QT prolongation. Am Heart J. 2001; 141(1): 111-116.

Bazett H: An analysis of the time relations of electrocardiograms. Heart. 1920; 7: 353-370.

Nelwan S, Meij S, Van Dam T, et al.: Correction of ECG variations caused by body position changes and electrode placement during ST-T monitoring. J Electrocardiol. 2001; 34(Suppl 2001): 213-216.

Luo S, Michler K, Johnston P, et al.: A comparison of commonly used QT correction formulae: The effect of heart rate on the QTc of normal ECGs. J Electrocardiol. 2004; 37(Suppl 1): 81-90.

Blake AD, Bot G, Freeman JC, et al.: Differential opioid agonist regulation of the mouse mu opioid receptor. J Biol Chem. 1997; 272(2): 782-790.

Bruera E, Sweeney C: Methadone use in cancer patients with pain: A review. J Palliat Med. 2002; 5(1): 127-138.

Anderson IB, Kearney T: Use of methadone. West J Med. 2000; 172: 43-46.

Barthwell A, Senay E, Marks R, et al.: Patients successfully maintained with methadone escaped human immunodeficiency virus infection. Arch Gen Psychiatr. 1989; 46: 957-958.

Goldstein A, Herrera J: Heroin addicts and methadone treatment in Albuquerque: A 22-year follow-up. Drug Alcohol Depend. 1995; 40(2): 139-150.

Ball JC, Lange WR, Myers CP, et al.: Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav. 1988; 29: 214-226.

Bell J, Mattick R, Hay A, et al.: Methadone maintenance and drug-related crime. J Subst Abuse. 1997; 9: 15-25.

Caplehorn JRM, Dalton M, Cluff MC, et al.: Retention in methadone maintenance and heroin addicts: Risk of death. Addiction. 1994; 89(2): 203-209.

Gerstein DR, Lewin LS: Treating drug problems. N Engl J Med. 1990; 323(12): 844-848.

McLellan AT, Arndt IO, Metzger DS, et al.: The effects of psychosocial services in substance-abuse treatment. JAMA. 1993; 269(15): 1953-1959.

Ling W, Wesson DR, Charuvastra C, et al.: A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatr. 1996; 53(5): 401-407.

Schottenfeld RS, Pakes JR, Oliveto A, et al.: Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatr. 1997; 54(8): 713-720.

Strain EC, Stitzer ML, Liebson IA, et al.: Methadone dose and treatment outcome. Drug Alcohol Depend. 1993; 33(2): 105-117.

Caplehorn JRM, Bell J: Methadone dosage and retention of patients in maintenance treatment. Med J Aust. 1991; 154(3): 195-199.

Maremmani I, Nardini R, Zolesi O, et al.: Methadone dosages and therapeutic compliance during a methadone-maintenance program. Drug Alcohol Depend. 1994; 34(2): 163-166.

Hartel DM, Schoenbaum EE, Selwyn PA, et al.: Heroin use during methadone-maintenance treatment—The importance of methadone dose and cocaine use. Am J Pub Health. 1995; 85(1): 83-88.

Ward J, Bell J, Mattick RP, et al.: Methadone maintenance therapy for opioid dependence—A guide to appropriate use. CNS Drugs. 1996; 6(6): 440-449.

Gossop M, Strang J, Connell PH: The response of outpatient opiate addicts to the provision of a temporary increase in their prescribed drugs. Br J Psychiatr. 1982; 141(OCT): 338-343.

Beaver WT, Wallenstein SL, Houde RW, et al.: Comparisons of analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. J Clin Pharmacol. 1977; 17(4): 186-198.

Davis MP, Walsh D: Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer. 2001; 9(2): 73-83.

Gorman AL, Elliott KJ, Inturrisi CE: The d- and l- isomers of methadone bind to the non-competitive site on the N-methyl-Daspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett. 1997; 223(1): 5-8.

Ebert B, Andersen S, Krogsgaard-Larsen P: Ketomidone, methadone, and pethidine are noncompetitive N-methyl-daspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett. 1995; 187(3): 165-168.

Trujillo K: Are NMDA receptors involved in opiate-induced neural and behavioral plasticity? A review of preclinical studies. Psychopharmacology. 2000; 151(2-3): 121-141.

He L, Whistler J: An opiate cocktail that reduces morphine tolerance and dependence. Curr Biol. 2005; 15(11): 1028-1033.